Skip to main content
Site navigation
College of Pharmacy and Allied Health Professions

Shafiqur Rahman

My picture

Title

Professor

Office Building

Avera Health and Science Center

Office

265

Mailing Address

Avera Health and Science 265
Pharmaceutical Sciences-Box 2202C
University Station
Brookings, SD 57007

Education

  • Ph.D. in neuropharmacology | Memorial University of Newfoundland, Canada
  • Postdoctoral fellowship in neuropsychopharmacology | Indiana University School of Medicine

Academic Interests

  • Pharmacology
  • Neuropharmacology
  • Drug addiction
  • Therapeutic drug discovery for neuropsychiatric and neurological disease
  • Public health policy on drug addiction and mental illness
  • Neuroethics
  • Neurotheology
  • Higher education

Academic Responsibilities

  • Pathophysiology, Pharmacology, Toxicology-I (PHA 352)
  • Pathophysiology, Pharmacology, Toxicology-II (PHA 353)
  • Pathophysiology, Pharmacology, Toxicology-III (PHA 452)
  • Pathophysiology, Pharmacology, Toxicology-IV (PHA 453)
  • Drugs of Abuse and Addiction (PHA 752)
  • Pharmacology I (PHA 442)
  • Pharmacology II (PHA 443)
  • Topics in Pharmaceutical Sciences (PHA 725/825)
  • Advanced Concepts in Pharmacology (PHA 740/840)
  • Techniques in Pharmaceutical Research (PHA 765)
  • Topics in Advanced Pharmacology (PHA 845)
  • Seminar in Pharmaceutical Sciences (PHA 890) 
  • Introduction to Pharmaceutical Sciences (PHA 720)
  • Medications and Wellness (PHA 201)

Committees and Professional Memberships

Committees

  • Chair, vice-chair, member, director on numerous institutional, professional and community service related committees (2008-present)

Professional Memberships

  • Society for Neuroscience (SFN)
  • American Society for Experimental Neurotherapeutics (ASENT)
  • American Society for Pharmacology and Experimental Therapeutics (ASPET)
  • American Association of Colleges of Pharmacy (AACP)
  • American Association of Pharmaceutical Scientists (AAPS)
  • International Brain Research Organization (IBRO)
  • Novel Global Community Educational Foundation (NGCEF)
  • Rho Chi Pharmacy Honor Society

Additional Professional Activities

  • Regional editor, CNS Neurological Disorders-Drug Targets (2016-present)
  • Editor, Effects of Peri-Adolescent Licit and Illicit Drug Use on the Developing CNS/International Review of Neuroscience (2020) 
  • Editor, Molecular Basis of Neuropsychiatric Disorders: from Bench to Bedside/Progress in Molecular Biology and Translational Science (2018)
  • Editor, Molecular Basis of Drug Addiction/Progress in Molecular Biology and Translational Science (2015)
  • Editor, Animal Models for Medications Screening to Treat Addiction/International Review of Neurobiology (2016)
  • Editor, Brain as a Drug Target/Progress in Molecular Biology and Translational Science (2011)
  • Editor, Drug Addiction and Brain Targets from Preclinical Research to Pharmacotherapy/CNS and Neurological Disorders-Drug Targets (2009)
  • Editorial board member, International Review of Neurobiology, International Journal of Physiology, Pathophysiology and Pharmacology (IJPPP), Current Drug Research Review, Drug Discoveries and Therapeutics, Current Drug Abuse Review, Journal of Addiction Research and Therapy, Frontiers Journals in Neuropharmacology, Aging and Neurodegeneration
  • Reviewer for 40 scientific journals related to drug addiction, neuroscience, pharmacology, and drug discovery research 
  • Evaluator, Accreditation Council for Pharmacy Education (ACPE) (2017)
  • Secretary/treasurer, American Society for Pharmacology and Experimental Therapeutics (ASPET)-Division of Pharmacology Education (2018-2020)
  • Co-chair, Teaching Institute for Graduate Pharmacology Education, American Society for Pharmacology and Experimental Therapeutics (ASPET) at the Experimental Biology Meeting in San Diego (2018)

Awards and Honors

  • 2019, Human and Civil Rights Award from South Dakota Education Association/National Education Association
  • 2018, Community Engagement Award, College of Pharmacy, South Dakota State University
  • 2015-2016, Academic Leadership Fellow, American Association of Colleges of Pharmacy
  • 2014, Distinguished Service Award, National Association on Mental Illness-South Dakota Chapter
  • 2013, TRiO Students’ Choice Award for Teaching, South Dakota State University
  • 2010, Distinguished Scholar and Researcher, College of Pharmacy, South Dakota State University
  • 2008, Fellow, American Foundation for Pharmaceutical Education
  • Clarke Foundation Postdoctoral Fellowship, University of Toronto, Canada 
  • Fellow, School of Graduate Studies, Memorial University of Newfoundland, Canada 
  • Memorial University of Newfoundland School of Medicine Graduate Fellowship, Canada 
  • Swedish Government Travel Fellowship for Higher Education

Grants

Research grants/support received as PI/CO-PI and advisor/mentor for research from the following funding agencies/organizations:

  • NIH/National Institute on Drug Abuse (R01DA009577 "Cholinergic and opiate mechanisms in drug reinforcement", 2001-2005).
  • NIH/National Institute on Alcohol Abuse and Alcoholism (R01AA013388 "Hippocampal neurotoxicity induced by ethanol withdrawal", 2008-2011).
  • Fulbright Foundation, USA 
  • American Foundation for Pharmaceutical Education (AFPE) 
  • American Association of Colleges of Pharmacy (AACP)
  • Saudi Arabia Cultural Mission (SACM), Washington DC, USA
  • Addiction Research Foundation 
  • Avera Research Institute/Avera Research Foundation
  • South Dakota Research and Development Innovation Grant/South Dakota Board of Regents
  • South Dakota State University (SDSU) Research Foundation
  • SDSU Academic Excellence Fund
  • SDSU Research Support Fund
  • SDSU Juhnke Endowment Fund 
  • South Dakota Governor's 2010 Research Initiative Fund 
  • University of Kentucky Research Foundation
  • Clark Foundation, University of Toronto, Canada
  • Canadian Institutes of Health Research

Areas of Research

  • Medication development for drug addiction and CNS disorders
  • Drug discovery for neuropsychiatric disorders
  • Drug discovery for neuroinflammatory and neuropathic pain 
  • Substance use disorder and co-morbid mental illness

Publications

  1. Alzarea S., Khan A., Ronan P., Lutfy K., Rahman S. The α-7 Nicotinic Receptor Positive Allosteric Modulator Alleviates Lipopolysaccharide Induced Depressive-like Behavior by Regulating Microglial Function, Trophic Factor and Chloride Transporters in Mice. Brain Sciences 2024, Volume 14, 290 (2024). DOI:10.3390/brainsci14030290
  2. Kumar D., Khan B., Okcay Y., Önal Sis, C., Abdallah A., Murray F., Sharma A., Uemura M., Taliyan R.; Heinbockel T., Rahman S., Goyal R. Dynamic Endocannabinoid-Mediated Neuromodulation of Retinal Circadian Circuitry, Ageing Research Reviews, 99, 102401 (2024). DOI:10.1016/j.arr.2024.102401
  3. Donlon J., Kumari P., Varghese S.P. and others, Rahman S., Stone T.W., Koola M.M., Integrative Pharmacology in the Treatment of Substance Use Disorders. Journal of Dual Diagnosis 20 (2): 132-177 (2024). DOI:10.1080/15504263.2023.2293854.
  4. Chen G., Rahman S., Lutfy K. E-cigarettes may serve as a gateway to conventional cigarettes and other addictive drugs. Advances in Drug and Alcohol Research. 3:11345 (2023). DOI:10.3389/ADAR.2023.11345 
  5. Alotaibi G., Khan A., Ronan P.J., Lutfy K., Rahman S.*. Glial Glutamate Transporter Modulation Prevents Development of Complete Freund’s Adjuvant-Induced Hyperalgesia and Allodynia in Mice. Brain Sciences 13(5), 807 (2023). DOI:10.3390/brainsci13050807
  6. Tolentino L., Iqbal A., Rahman S., Lutfy K. The Role of Beta-Endorphin in Food Deprivation-Mediated Increases in Food Intake and Binge-Eating. Brain Sciences 13(2):212 (2023). DOI:10.3390/brainsci13020212
  7. Islam N., Cichero E., Rahman S., Ranasinghe I. Novel Pulmonary Delivery of Drugs for the Management of Atrial Fibrillation. American Journal of Cardiovascular Drugs. 23, 1-7 (2023). DOI:10.1007/s40256-022-00551-8.
  8. Alzarea S., Abbas M., Ronan P.J., Lutfy K., Rahman S.*. The Effect of an α-7 Nicotinic Allosteric Modulator PNU120596 and NMDA Receptor Antagonist Memantine on Depressive-like Behavior Induced by LPS in Mice: The Involvement of Brain Microglia. Brain Sciences 12 (11):1493 (2022). DOI:10.3390/brainsci12111493
  9. Kumar D., Sharma A., Taliyan R., Urmera M.T., Herrera-Calderon O., Heinbockel T., Rahman S., Goyal R. Orchestration of the circadian clock and its association with Alzheimer's disease: Role of endocannabinoid signaling. Ageing Research Reviews. 73, 101533 (2022). DOI:10.1016/j.arr.2021.101533.
  10. Rahman S.*, Rahman Z.I., Ronan P.J., Lutfy K., Bell R.L. Adolescent Opioid Abuse: Role of Glial and Neuroimmune Mechanisms. International Review of Neurobiology 161, 147-165 (2021).DOI:10.1016/bs.irn.2021.07.003.
  11. Islam N., Rahman S.*. Novel Pulmonary Delivery of Antiviral Drugs for Treating COVID-19 in Patients with Parkinson’s Disease. Current Drug Delivery 19, 260-265 (2022). DOI:10.2174/1567201818666210331121803.
  12. Tschetter K.E., Callahan L.B., Flynn S.A., Rahman S., Beresford T.P., Ronan P.J. Early life stress and susceptibility to addiction in adolescence. International Review of Neurobiology 161:277-302 (2021). DOI:10.1016/bs.irn.2021.08.007.
  13. Rahman S.*,  Bell R.L. Future directions for part I: Substance use disorder in adolescence-A vision for a better future. International Review of Neurobiology 160, 341-344 (2021). DOI:10.1016/bs.irn.2021.08.008.
  14. Abbas M., Alzarea S., Papke R.L., Rahman S.*. Effects of α-7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator on BDNF, NKCC1 and KCC2 Expression in the Hippocampus following Lipopolysaccharide-induced Allodynia and Hyperalgesia in a Mouse Model of Inflammatory Pain. CNS and Neurological Disorders Drug Targets 20, 366-377 (2021). DOI:10.2174/1871527319666201230102616.
  15. Chen G., Ghazal M., Rahman S., Lutfy K. The Impact of Adolescent Nicotine Exposure on Alcohol Use During Adulthood: The Role of Neuropeptides. International Review of Neurobiology, 161, 53-93 (2021). DOI:10.1016/bs.irn.2021.07.006.
  16. Hauser S.R., Rodd Z.A., Deehan G.A., Liang T., Rahman S., Bell R.L. Effects of Adolescent Substance Use Disorders on Central Cholinergic Function. International Review of Neurobiology 160, 175-221 (2021). DOI:10.1016/bs.irn.2021.07.008.
  17. Rahman S.*, Bell R.L. Nicotinic Cholinergic Mechanisms in Alcohol Abuse and Dependence. Neuroscience of Alcohol-Mechanisms and Treatment 427-433 (2019).
  18. Rahman S.*, Alzarea, S. Glial mechanisms underlying major depressive disorder: Potential therapeutic opportunities. Progress in Molecular Biology and Transnational Science 167, 159-178 (2019). DOI:10.1016/bs.pmbts.2019.06.010.
  19. Rahman S.*, Bell R.L. Nicotinic Cholinergic Mechanisms in Alcohol Abuse and Dependence. Neuroscience of Alcohol-Mechanisms and Treatment 427-431 (2019).
  20. Bell R.L., Sari Y., Rahman S. Alcohol and central glutamate activity: What goes up must come down. Neuroscience of Alcohol-Mechanisms and Treatment 453-461 (2019).
  21. Abbas M., Alzarea S., Papke R.L., Rahman S.*. The α-7 nicotinic acetylcholine receptor positive allosteric modulator prevents lipopolysaccharide-induced allodynia, hyperalgesia and TNF-alpha in the hippocampus in mice. Pharmacological Reports 71, 1168-1176 (2019).
  22. Phelps B.J., Miller T.M., Arens H., Hutchinson T., Lang K.A., Muckey L.M., Thompson N., Stanage S., Rahman S., Rawls S.M. Cotinine Establishes a Conditioned Place Preference with Planarians. Neuroscience Letters 703, 145-148 (2019).
  23. Alzarea S., Rahman S.*. α-7 nicotinic receptor allosteric modulator PNU120596 prevents lipopolysaccharide-induced anxiety, cognitive deficit and depression-like behaviors in mice. Behavioral Brain Research 366,19-28 (2019).
  24. Alotaibi G., Rahman S.*. Effects of astroglial glutamate transporter activator in formalin-induced pain behavior in mice. European Journal of Pain 23, 765-783 (2019).
  25. Alzarea S., Rahman S.*. Effects of α-7 nicotinic allosteric modulator PNU 120596 on depressive-like behavior after lipopolysaccharide administration in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry 86, 218-228 (2018).
  26. Roni M.A., Rahman S.*. Lobeline attenuates ethanol withdrawal-induced depression-like behavior in mice. Alcohol 61, 63-70 (2017).
  27. Abbas M., Alzarea S., Papke R.L., Rahman S.*. The α-7 nicotinic acetylcholine receptor positive allosteric modulator Attenuates lipopolysaccharide-induced activation of hippocampal IκB and CD11b gene expression in mice. Drug Discoveries and Therapeutics 11, 206-211 (2017).
  28. Islam N., Abbas M., Rahman S.*. Neuropathic pain and lung delivery of nanoparticulate drugs: an emerging novel therapeutic strategy. CNS and Neurological Disorders - Drug Targets 16, 303-310 (2017).
  29. Abbas M., Rahman S.*. Effects of α-7 nicotinic acetylcholine receptor positive allosteric modulator on lipopolysaccharide-induced neuroinflammatory pain in mice. European Journal of Pharmacology 783, 85-91 (2016).
  30. Bell R.L., Hauser S., Rodd Z.A., Liang T., Sari Y., McClintick J., Rahman S., Engleman E.A. A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction. International Review of Neurobiology 126, 179-260 (2016).
  31. Rahman S.*, Engleman E.A., Bell R.L. Recent Advances in Nicotinic Receptor Signaling in Alcohol Abuse and Alcoholism. Progress Molecular Biology and Translational Science 137,183-201 (2016).
  32. Bell R.L., Hauser S.R., McClintick J., Rahman S., Edenberg H.J., Szumlinski K.K., McBride W.J. Ethanol-Associated Changes in Glutamate Reward Neurocircuitry: A Minireview of Clinical and Preclinical Genetic Findings. Progress in Molecular Biology and Translational Science 137, 41-85 (2016).
  33. Sajja R.K., Rahman S., Cucullo L. Drugs of abuse and blood-brain barrier endothelial dysfunction: A focus on the role of oxidative stress. Journal of Cerebral Blood Flow and Metabolism, 36, 539-554 (2016).
  34. Roni M.A., Rahman S.*. Effects of lobeline and reboxetine, fluoxetine, or bupropion combination on depression-like behaviors in mice. Pharmacology Biochemistry and Behavior 139, 1-6 (2015).
  35. Rahman S.*, Engleman E.A., Bell R.L. Nicotinic receptor modulation to treat alcohol and drug dependence. Frontiers in Neuroscience-Neuropharmacology 8, (426), 1-11 (2015).
  36. Roni M.A., Rahman S.*. The effects of lobeline on depression-like behavior and hippocampal dell proliferation following chronic unpredictable stress in mice. Neuroscience Letters 584, 7-11 (2015).
  37. Roni M.A., Rahman S.*. The effects of lobeline on nicotine withdrawal-induced depression-like behavior in mice. Psychopharmacology  231, 2989-2998 (2014).
  38. Sajja R.K., Rahman S.*. Nicotinic receptor partial agonists modulate alcohol deprivation effect in C57BL/6J in mice. Pharmacology Biochemistry and Behavior 110, 161-167 (2013).
  39. Rahman S.*. Nicotinic Receptors as Therapeutic Targets for Drug Addictive Disorders. CNS and Neurological Disorders-Drug Targets 12, 633-640 (2013).
  40. Sajja R.K., Rahman S.*. Cytisine modulates chronic voluntary ethanol consumption and ethanol-induced striatal up-regulation of Delta FosB in mice. Alcohol 47, 299-307 (2013).
  41. Roni M.A., Rahman S.*. Antidepressant-like effects of lobeline in mice: behavioral, neurochemical and neuroendocrine evidence. Progress in Neuro-Psychopharmacology and Biological Psychiatry 41, 44-51 (2013).
  42. Rahman S.*, Prendergast M.A. Brain cholinergic receptor system as a target for treating alcohol dependence. Recent Patents on CNS Drug Discovery 7, 145-150 (2012).
  43. Sajja R.K., Rahman S.*. Nicotinic receptor ligands modulate chronic nicotine-induced ethanol consumption in C57BL/6J mice. Pharmacology Biochemistry and Behavior 102, 36-43 (2012).
  44. Islam N., Rahman S.*. Improved treatment of nicotine addiction and pulmonary drug delivery. Drug Discovery and Therapeutics, 6, 123-132 (2012).
  45. Roni M.A., Rahman S.*. Neuronal nicotinic receptor ligand lobeline reduces anxiety-like behavior in mice. Neuroscience Letters 504, 237-241 (2011).
  46. Sajja R.K., Rahman S.*. Lobeline and cytisine reduce voluntary ethanol drinking behavior in male C57BL/6J mice.   Progress in Neuro-Psychopharmacology and Biological Psychiatry 35, 257-264 (2011).
  47. Rahman S.*. Brain nicotinic receptors as emerging targets for drug addiction: neurobiology to transnational science. Progress in Molecular Biology and Translational Science 98, 349-365 (2011).
  48. Sajja R.K., Dwivedi, C., Rahman S*. Nicotinic ligands modulate ethanol-induced dopamine function in mice.  Pharmacology 86,168-73 (2010).
  49. Meyer A.C., Rahman S., Charnigo R.J., Dwoskin L.P., Crabbe J.C., Bardo M.T. Genetics of novelty seeking, amphetamine self-administration and reinstatement using inbred rats. Genes, Brain and Behavior 9, 790-798 (2010).
  50. Rahman S.*. Targeting opioid receptors treatment for brain disorders. CNS and Neurological Disorders - Drug Targets 9, 128 (2010).
  51. Hasan S.M.R., Hossain M.M., Akter R., Jamila M., Mazumder M.E.H., Alam M.A., Faruque A., Rana S., Rahman S.*. Analgesic activity of the different fractions of the aerial parts of Commelina benghalensis Linn. International Journal of Pharmacology 6, 63-67 (2010).
  52. Bell R.L., Eiler B.A., Cook J.B., Rahman S.*. Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats. Alcohol 43, 581-592 (2009).
  53. Hasan S.M.R., Jamila M., Majumder M.M., Akter R., Hossain M.M., Mazumder M.E.H., Alam M.A., Jahangir R., Rana M.S., Arif M. and Rahman S*. Analgesic and antioxidant activity of the Hydromethanolic extract of Mikania scandens (L.) Willd. Leaves. American Journal of Pharmacology Toxicology 4, 1-7 (2009).
  54. Hasan S.M.R., Hossain M.M., Akter R., Jamila M., Mazumder M.E.H., Faruque A., Rahman S.*. Sedative and anxiolytic effects of different fractions of Commelina benghalensis. Drug Discoveries and Therapeutics 3, 221-227 (2009).
  55. Hasan S.M.R., Hossain M.M., Akter R., Jamila M., Mazumder M.E.H., Rahman, S*. DPPH free radical scavenging activity of some Bangladeshi medicinal plants. Journal of Medicinal Plants Research, 3, 875-879 (2009).
  56. Rahman S.*. Drug Addiction and Brain Targets: from Preclinical research to Pharmacotherapy. CNS and Neurological Disorders-Drug Targets 7, 391-392 (2008).
  57. Rahman S.*, Lopez-Hernandez G., Corrigall W.A., Papke R.L., Neuronal nicotinic receptors as brain targets for pharmacotherapy of drug addiction. CNS and Neurological Disorders - Drug Targets 7, 422-441 (2008).
  58. Rahman S., Neugebauer N.M., Zhang Z., Crooks P.A., Dwoskin L.P., Bardo M.T., The novel nicotinic receptor antagonist N,N’-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens. European Journal of Pharmacology 601, 103-105 (2008).
  59. Rahman S., Zhang Z., Crooks P.A., Dwoskin L.P., Bardo M.T. Region-specific effects of N,N’-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on nicotine-induced increase in extracellular dopamine in vivo. British Journal of Pharmacology 153, 792–804 (2008).
  60. Rahman S., Bardo M.T. Environmental enrichment increases amphetamine-induced glutamate neurotransmission in the nucleus accumbens: a neurochemical study. Brain Research 1197, 40-46 (2008).
  61. Islam N., Rahman S.*, Pulmonary drug delivery: Implication for new strategy for pharmacotherapy of neurodegenerative disorders. Drug Discoveries and Therapeutics 5, 264-276 (2008).
  62. Mazumder M.E.H., Rahman S.*. Pharmacological evaluation of Bangladeshi Medicinal Plants for antioxidant activity. Pharmaceutical Biology 46, 704-709 (2008)
  63. Rahman S., Neugebauer N.M., Zhang Z., Crooks P.A., Dwoskin L.P., Bardo M.T. The effects of novel N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide on acute and repeated nicotine-induced increases in extracellular dopamine response in rat nucleus accumbens. Neuropharmacology 52, 755-763 (2007).
  64. Rahman S.*, Zhang J., Engleman E., Corrigall W.A. Neuroadaptive changes in mesolimbic dopamine system after chronic nicotine self-administration: A microdialysis study. Neuroscience 129, 415-424 (2004).
  65. Rahman S.*, Zhang J., Corrigall W.A. Local perfusion of nicotine differentially modulates somatodendritic dopamine release in the rat ventral tegmental area after nicotine pre-exposure. Neurochemical  Research 29, 1687-1693 (2004).
  66. Rahman S.*, Zhang J., Corrigall W.A. Effect of nicotine exposure on sulpiride-induced dopamine release in the nucleus accumbens. European Journal Pharmacology 494, 31-34 (2004).
  67. Rahman S.*, Zhang J., Corrigall, W.A. Effects of acute and chronic nicotine on somatodendritic dopamine release of the rat ventral tegmental area in vivo microdialysis study. Neuroscience Letters 348, 61-64 (2003).
  68. Rahman S., McBride W.J. Involvement of GABA and cholinergic receptors in the nucleus accumbens on feedback control of somatodendritic dopamine release in the VTA. Journal of Neurochemistry 80, 646-654 (2002).
  69. Rahman S. and McBride W.J. Dopamine D1-D2 receptor interaction within the nucleus accumbens mediates long-loop negative feedback to the VTA. Journal of Neurochemistry 77, 1248-1255 (2001).
  70. Rahman S., Engleman E., Simon J. and McBride W.J. Negative interaction of D2 receptor antagonist and GBR-12909 and GBR 12935 dopamine uptake inhibitors in the nucleus accumbens. European Journal Pharmacology 414, 37-44 (2001).
  71. Rahman S.*, Hasnat A., Hasan C.M., Rashid M.A. and Ilias M. Pharmacological Evaluation of traditionally used medicinal plants of Bangladesh. Pharmaceutical Biology 39, 1-6 (2001).
  72. Rahman S., McBride W.J. Feedback control of mesolimbic somatodendritic dopamine release in rat brain. Journal of Neurochemistry 74, 684-692 (2000).
  73. Rahman S., Li P.P., Kish S.J., Young L.T., Kofman O., Warsh J.J. Reduced [3H]cAMP binding in bipolar affective disorder. Journal of Neurochemistry 68, 297-304 (1997).
  74. Kofman O., Rahman S., Li P.P., Warsh J.J. Lithium and carbamazepine differentially affect locomotion and cAMP binding stimulated by cholera toxin. Biological Psychiatry, 39, 594-595 (1996).
  75. Rahman S., Li P.P., Kish S.J., Young L.T., Warsh J.J. Decreased [3H] cAMP binding in postmortem brain in bipolar disorder. Biological Psychiatry, 39, 583-584 (1996).
  76. Rahman S. and Neuman R.S. Calcimycin, cyclopiazonic acid and Thapsigargin mimic 5-hydroxytryptamine in facilitating N-methyl-D-aspartate depolarization of cortical neurons. British Journal of Pharmacology 119, 877-884 (1996).
  77. Rahman S., Neuman R.S. Characterization of metabotropic glutamate receptor mediated facilitation of N-methyl-D-aspartate depolarization of neocortical neurons. British Journal of Pharmacology 117, 675-683 (1996).
  78. Rahman S., McLean J., Darby-King A., Paterno G., Reynolds J., Neuman R.S. Loss of cortical serotonin 5-HT2A signal transduction in senescent rats: reversal following inhibition of protein kinase Cognitive Neuroscience 66, 891-901 (1995).
  79. Neuman R.S., Rahman S. Calcium mobilizing compounds mimic 5-HT Induced facilitation of N-methyl-D-aspartate depolarization. Behavioral Brain Research 73, 273-275 (1995).
  80. Rahman S., Neuman R.S. Multiple mechanisms of serotonin (5-HT2A) Receptor desensitization. European Journal of Pharmacology 238, 173-180 (1993).
  81. Rahman S., Neuman R.S. Myo-inositol reduces serotonin (5-HT2A) Receptor induced homologous and heterologous desensitization. Brain Research 631, 349-351 (1993).
  82. Rahman S., Neuman R.S. Activation of 5-HT2A receptors facilitates depolarization of neocortical neurons by N-methyl-D-aspartate. European Journal of Pharmacology 231, 347-354 (1993).

Department(s)